Amneal Pharmaceuticals (AMRX) Competitors $9.36 -0.02 (-0.21%) Closing price 04:00 PM EasternExtended Trading$9.37 +0.01 (+0.12%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRX vs. QGEN, MRNA, BBIO, VRNA, ELAN, BPMC, ROIV, GRFS, LEGN, and RVMDShould you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Amneal Pharmaceuticals vs. Its Competitors QIAGEN Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Grifols Legend Biotech Revolution Medicines Qiagen (NYSE:QGEN) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Which has more volatility & risk, QGEN or AMRX? Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Is QGEN or AMRX more profitable? Qiagen has a net margin of 18.30% compared to Amneal Pharmaceuticals' net margin of 0.12%. Qiagen's return on equity of 14.77% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen18.30% 14.77% 8.87% Amneal Pharmaceuticals 0.12%-189.49%6.17% Do institutionals and insiders hold more shares of QGEN or AMRX? 70.0% of Qiagen shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor QGEN or AMRX? In the previous week, Amneal Pharmaceuticals had 7 more articles in the media than Qiagen. MarketBeat recorded 20 mentions for Amneal Pharmaceuticals and 13 mentions for Qiagen. Qiagen's average media sentiment score of 1.40 beat Amneal Pharmaceuticals' score of 1.13 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 16 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, QGEN or AMRX? Qiagen has higher earnings, but lower revenue than Amneal Pharmaceuticals. Qiagen is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B5.39$83.59M$1.6928.40Amneal Pharmaceuticals$2.79B1.05-$116.89M$0.01936.00 Do analysts rate QGEN or AMRX? Qiagen currently has a consensus target price of $49.69, suggesting a potential upside of 3.51%. Amneal Pharmaceuticals has a consensus target price of $11.60, suggesting a potential upside of 23.93%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryQiagen and Amneal Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRX vs. The Competition Export to ExcelMetricAmneal PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.94B$2.48B$5.74B$9.78BDividend YieldN/A1.67%4.40%4.04%P/E Ratio936.9422.5330.8326.39Price / Sales1.05506.55382.9086.63Price / Cash6.68178.3537.7259.11Price / Book-26.006.2910.106.62Net Income-$116.89M$32.94M$3.26B$265.42M7 Day Performance-0.53%2.27%3.90%3.58%1 Month Performance16.13%1.06%3.73%0.46%1 Year Performance10.38%5.65%37.68%19.41% Amneal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRXAmneal Pharmaceuticals3.0497 of 5 stars$9.36-0.2%$11.60+23.9%+10.7%$2.94B$2.79B936.948,100Positive NewsInsider TradeQGENQIAGEN4.0132 of 5 stars$48.66-1.4%$49.69+2.1%+11.3%$10.97B$1.98B28.755,765News CoverageMRNAModerna4.4987 of 5 stars$28.09+0.2%$43.59+55.2%-69.7%$10.90B$3.24B-3.735,800BBIOBridgeBio Pharma4.293 of 5 stars$49.02-4.5%$61.35+25.2%+88.7%$9.81B$221.90M-11.99400VRNAVerona Pharma PLC American Depositary Share2.4814 of 5 stars$105.79+0.5%$109.00+3.0%+295.9%$8.96B$42.28M-106.8630Positive NewsELANElanco Animal Health2.8542 of 5 stars$17.72-1.4%$17.33-2.2%+23.6%$8.92B$4.44B20.609,000Gap UpBPMCBlueprint MedicinesN/A$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640News CoverageROIVRoivant Sciences3.1985 of 5 stars$11.81-0.3%$16.50+39.7%+0.5%$8.06B$29.05M-16.87860GRFSGrifols3.5922 of 5 stars$10.58-1.3%$10.30-2.6%+14.3%$7.37B$7.45B9.0423,822LEGNLegend Biotech3.8769 of 5 stars$37.45-0.1%$72.38+93.3%-38.1%$6.89B$627.24M-42.562,609News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.3959 of 5 stars$36.45+0.4%$69.54+90.8%-15.4%$6.79B$11.58M-8.10250Positive News Related Companies and Tools Related Companies QGEN Competitors MRNA Competitors BBIO Competitors VRNA Competitors ELAN Competitors BPMC Competitors ROIV Competitors GRFS Competitors LEGN Competitors RVMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRX) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access